I don’t know the details of how the market is split. I do know that Pfizer recently had a drug approved for ATTR-CM (VYNDAQEL)which costs around 225k a year. I am sure even if that is the case, with the limited time they have, the reps are going to focus on that as they will make a lot more money on that. To your point though, Canada was never going to be a big driver of revenue and financial success for the company.
Market Data 
Markets 
AI
